

Serial No.: 09/937,009

- 4 -

**REMARKS**

In view of the above amendments and the following remarks, reconsideration of the outstanding office action is respectfully requested.

The objections to claims 1, 12 and 23 have been overcome in view of the above amendments. Support for new claims 52 is found at page 12, lines 19-20. Support for claim 53 is found at page 18, line 28-page 19, line 3, page 29, lines 1-6 and page 54, lines 17-22.

The rejections of claims 4 and 12 for indefiniteness are respectfully traversed in view of the above amendments. Applicants further point out that the interacting polypeptide comprises SEQ ID NO: 25 and the substrate polypeptide comprises SEQ ID NO: 30, accordingly it is clear in the claims which polypeptide is covered.

The rejection of claims 1, 4-5, 12 and 23 under 35 U.S.C. §112 (first paragraph) for lack of written description and enablement is respectfully traversed in view of the above amendments.

For general background, applicants point out that the specification as filed contained a description of PDK1 at, for example, page 4, line 11 to page 5, line 15 and Figure 10. PRK2 is described in the specification as filed, for example, on page 3, lines 10-14, page 8, line 26-page 9, line 2, page 10, line 22-page 12, line 17 and Figure 11. The claim amendments as submitted herewith and in the amendment mailed with a certificate of mailing dated November 21, 2005, therefore, include no new matter.

C:\Clients\002\00170\supplemental amendment.wpd

Serial No.: 09/937,009

- 5 -

In view of the foregoing, applicants believe the present case to be in condition for allowance and such allowance is earnestly solicited.

Respectfully submitted,

February 10, 2006  
Date

Karla M. Weyand  
Karla M. Weyand  
Reg. No. 40,223

Rogalskyj & Weyand, LLP  
P.O. Box 44  
Livonia, New York 14487-0044  
Tel: 716-626-5380  
Fax: 716-626-5384

C:\Clients\002\00170\supplemental amendment.wpd